Ice-based lipid nanoparticle formulation for delivery of mRNA
The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.
1. A composition formulated for pulmonary delivery of messenger RNA (mRNA) therapy comprising:
an mRNA encoding a therapeutic protein; and
lipid nanoparticles encapsulating the mRNA and comprising no more than three distinct lipids,
wherein one distinct lipid is imidazole cholesterol ester (ICE) and constitutes at least 50% but less than 65% molar ratio of the three distinct lipids, and
further wherein the lipid nanoparticles have an encapsulation percentage for mRNA of at least 80% and have an average diameter of less than 100 nm.
2. The composition of claim 1 , wherein the lipid nanoparticles have an average diameter of less than 80 nm.
3. The composition of claim 2 , wherein the mRNA is codon-optimized.
4. The composition of claim 3 , wherein the mRNA comprises a 5′ cap structure.
5. The composition of claim 4 , wherein the mRNA comprises a 5′ untranslated region.
6. The composition of claim 5 , wherein the mRNA comprises a 3′ untranslated region.
7. The composition of claim 6 , wherein the mRNA comprises a 3′ tail structure comprising a poly(A) tail.
8. The composition of claim 7 , wherein the mRNA encodes a CFTR protein.
9. The composition of claim 2 or 8 , wherein the mRNA comprises one or more modified nucleotides.
10. A method of delivering messenger RNA (mRNA) in vivo comprising administering by pulmonary delivery to a subject in need of delivery a composition comprising:
an mRNA encoding a therapeutic protein; and
lipid nanoparticles encapsulating the mRNA and comprising no more than three distinct lipids,
wherein one distinct lipid is imidazole cholesterol ester (ICE) and constitutes at least lipids,
wherein one distinct lipid is imidazole cholesterol ester (ICE) and constitutes at least 50% but less than 65% molar ratio of the three distinct lipids, and
further wherein the lipid nanoparticles have an encapsulation percentage for mRNA of at least 80% and have an average diameter of less than 100 nm,
thereby delivering mRNA to a subject in need.
11. The method of claim 10 , wherein the lipid nanoparticles have an average diameter of less than 80 nm.
12. The method of claim 11 , wherein the mRNA is codon-optimized.
13. The method of claim 12 , wherein the mRNA comprises a 5′ cap structure and a 5′ untranslated region.
14. The method of claim 13 , wherein the mRNA comprises a 3′ untranslated region and a 3′ tail structure comprising a poly(A) tail.
15. The method of claim 14 , wherein the mRNA encodes a CFTR protein.
16. The method of claim 11 or 15 , wherein the mRNA comprises one or more modified nucleotides.
17. The method of claim 11 or 15 , wherein the pulmonary delivery comprises nebulization.